No difference in the primary end point seen with any of the three medications versus placebo among adults with overweight or obesity
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
FRIDAY, Aug. 19, 2022 (HealthDay News) -- For patients with COVID-19 infection, metformin, ivermectin, and fluvoxamine do not prevent the occurrence of hypoxemia, an emergency department visit, hospitalization, or death, according to a study published in the Aug. 18 issue of the New England Journal of Medicine.
Carolyn T. Bramante, M.D., M.P.H., from the University of Minnesota in Minneapolis, and colleagues used a 2-by-3 factorial design to test the effectiveness of metformin, ivermectin, and fluvoxamine in preventing serious severe acute respiratory syndrome coronavirus 2 infection in nonhospitalized adults enrolled within three days after a confirmed diagnosis of infection and less than seven days after symptom onset. Patients were aged 30 to 85 years, and all had overweight or obesity. The primary analysis included 1,323 patients.
The researchers found that the adjusted odds ratios (95 percent confidence intervals) for a primary event (hypoxemia, emergency department visit, hospitalization, or death) were 0.84 (0.66 to 1.09), 1.05 (0.76 to 1.45), and 0.94 (0.66 to 1.36) with metformin, ivermectin, and fluvoxamine, respectively. In prespecified secondary analyses, the adjusted odds ratios (95 percent confidence intervals) for emergency department visit, hospitalization, or death were 0.58 (0.34 to 0.94), 1.39 (0.72 to 2.69), and 1.17 (0.57 to 2.40) with metformin, ivermectin, and fluvoxamine, respectively, while the corresponding adjusted odds ratios (95 percent confidence intervals) for hospitalization or death were 0.47 (0.20 to 1.11), 0.73 (0.19 to 2.77), and 1.11 (0.33 to 3.76).
"None of the trial drugs resulted in a lower severity of symptoms than identically matched placebo," the authors write.
The fluvoxamine placebo tablets were donated by Apotex. The ivermectin placebo and active tablets were donated by Edenbridge. Two authors disclosed financial ties to Medtronic.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Updated on September 21, 2022
Read this Next
Other Trending Articles